Group 1 - The article discusses the recent IPO counseling registrations of eight companies, including Tengli Transmission, Fangyi Co., and Huasheng Radar, indicating a trend of companies preparing for public offerings in China [1] - Tengli Transmission, which previously withdrew its IPO application in July 2024, is now seeking to re-enter the market with a focus on automotive components [3][4] - Fangyi Co. has recently completed a targeted financing of 60 million yuan and is preparing for an IPO on the Beijing Stock Exchange [7][8] - Huasheng Radar, a specialized radar technology company, has secured significant investment and has reported a doubling of orders in the first half of 2024 compared to its 2023 revenue [12][13] - Honor is positioning itself to become the third publicly listed smartphone giant in China, following Xiaomi and Transsion Holdings, with its IPO application submitted in June 2025 [14][15][16] - Lansheng Biotechnology, a low-toxicity pesticide manufacturer, has also initiated its IPO counseling, with a current valuation of 1.752 billion yuan [18][19][21] - Peiyuan Co., a hidden champion in the automotive shock absorber sector, is facing revenue growth without corresponding profit increases, indicating potential operational challenges [22] - Ziguang Zhanrui is preparing for an IPO on the Sci-Tech Innovation Board, aiming to become the first publicly listed domestic smartphone chip company, with a post-investment valuation of approximately 70 billion yuan [24][26] Group 2 - Tengli Transmission's revenue has shown consistent growth from 2020 to 2023, with total revenues of 2.92 billion yuan, 3.77 billion yuan, 5.10 billion yuan, and 6.1 billion yuan respectively, indicating a strong upward trend [5] - Fangyi Co. reported revenues of 1.93 billion yuan, 2.05 billion yuan, and 2.53 billion yuan from 2022 to 2024, but its net profit has seen a decline, highlighting profitability issues despite revenue growth [11] - Huasheng Radar's revenue for 2023 was 2.4 billion yuan, with a significant increase in orders in 2024, suggesting strong market demand for its products [13] - Lansheng Biotechnology's financial data shows a net profit of 2.69 billion yuan for 2024, with a focus on developing green pesticides and holding 39 patents [19][21] - Peiyuan Co. reported revenues of 6.34 billion yuan and 6.72 billion yuan for 2023 and 2024, respectively, but faced a decline in net profit, indicating operational challenges [22] - Ziguang Zhanrui's revenue figures for 2022, 2023, and 2024 were 14 billion yuan, 13 billion yuan, and 14.5 billion yuan, respectively, but the company has yet to achieve profitability [26]

6月23日至29日，证监会新增披露，杭州腾励传动科技股份有限公司（下称"腾励传动"）、江苏方意摩擦材料股份有限公司（下 称"方意股份"）、浙江华盛雷达股份有限公司（下称"华盛雷达"）、荣耀终端股份有限公司（下称"荣耀"）、兰升生物科技集团股 份有限公司（下称"兰升生物"）、宁波培源股份有限公司（下称"培源股份"）、紫光展锐（上海）科技股份有限公司（下称"紫光展 锐"）、宏泽（江苏）科技股份有限公司（下称"宏泽科技"）等8家公司进行了辅导备案。 IPO日报注意到，腾励传动曾于2024年7月撤回创业板上市申请，时隔一年再次辅导；方意股份6月22日刚刚定向增发融资6000万 元，现辅导备案；华盛雷达共经历了七轮融资，吸引了包括中信建投资本、维度资本、国民创投在内的多家知名投资机构；荣耀或 成中国第三家上市的智能手机巨头；国开金融、河北产业投资引导基金参投的兰升生物现估值17.52亿元；国内汽车减震器活塞杆领 域的隐形冠军遭遇增收不增利问题；紫光展锐有望冲击国产智能手机芯片第一股，公司投后估值已达700亿元左右；宏泽科技2024年 营业收入和净利润明显下滑。 AI制图 一年前创业板上市失败 腾励传动于2025年6月2 ...

腾励传动重启上市。 6月23日证监会网站显示，杭州腾励传动科技股份有限公司（简称"腾励传动"）向浙江证监局提交了上 市辅导报告，辅导机构为国泰海通。 值得注意的是，腾励传动并非首次闯关上市。2023年4月，腾励传动向深交所报送首次公开发行股票并 在创业板上市申请材料，拟募资4.29亿元。但在2024年7月，腾励传动撤回上市申请。 根据早前披露的招股书显示，腾励传动专业从事汽车等速驱动轴零配件及总成的研发、生产和销售。公 司长期以来专注于乘用车市场，持续为知名一级供应商配套生产等速驱动轴核心零配件，也具备为整车 厂商提供等速驱动轴总成整体解决方案的能力，是国内少数进入知名整车厂商供应体系的等速驱动轴制 造企业之一。 腾励传动是国家级专精特新"小巨人"企业、浙江省专精特新中小企业、国家高新技术企业。腾励传动主 要产品包括等速驱动轴零配件及其总成，零配件主要包含保持架、中间轴以及内外星轮等产品；此外， 公司亦生产部分电驱连接轴产品。等速驱动轴是汽车传动系统的关键部件之一，通常安装在汽车轮毂与 变速箱（或电机）之间，使变速箱（或电机）的扭矩通过左右两根等速驱动轴平稳可靠地传递到汽车驱 动轮，亦能满足汽车转向要求并补偿 ...